| International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical … BT Tsuji, JM Pogue, AP Zavascki, M Paul, GL Daikos, A Forrest, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39 (1 …, 2019 | 836 | 2019 |
| Tocilizumab for treatment of mechanically ventilated patients with COVID-19 EC Somers, GA Eschenauer, JP Troost, JL Golob, TN Gandhi, L Wang, ... Clinical Infectious Diseases 73 (2), e445-e454, 2021 | 546 | 2021 |
| Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections HJ Morrill, JM Pogue, KS Kaye, KL LaPlante Open forum infectious diseases 2 (2), ofv050, 2015 | 536 | 2015 |
| Infections caused by resistant gram‐negative bacteria: epidemiology and management KS Kaye, JM Pogue Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35 (10 …, 2015 | 481 | 2015 |
| Coronavirus disease 2019 treatment: a review of early and emerging options EK McCreary, JM Pogue Open forum infectious diseases 7 (4), ofaa105, 2020 | 442 | 2020 |
| Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system JM Pogue, J Lee, D Marchaim, V Yee, JJ Zhao, T Chopra, P Lephart, ... Clinical infectious diseases 53 (9), 879-884, 2011 | 438 | 2011 |
| Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non … RG Wunderink, Y Matsunaga, M Ariyasu, P Clevenbergh, R Echols, ... The Lancet Infectious Diseases 21 (2), 213-225, 2021 | 390 | 2021 |
| Outbreak of Colistin-Resistant, Carbapenem-Resistant Klebsiella pneumoniae in Metropolitan Detroit, Michigan D Marchaim, T Chopra, JM Pogue, F Perez, AM Hujer, S Rudin, ... Antimicrobial agents and chemotherapy 55 (2), 593-599, 2011 | 273 | 2011 |
| A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity NA Finch, EJ Zasowski, KP Murray, RP Mynatt, JJ Zhao, R Yost, ... Antimicrobial agents and chemotherapy 61 (12), 10.1128/aac. 01293-17, 2017 | 247 | 2017 |
| Agents of last resort: polymyxin resistance KS Kaye, JM Pogue, TB Tran, RL Nation, J Li Infectious Disease Clinics 30 (2), 391-414, 2016 | 212 | 2016 |
| Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin–tazobactam compared to those on vancomycin and cefepime B Navalkele, JM Pogue, S Karino, B Nishan, M Salim, S Solanki, ... Clinical Infectious Diseases 64 (2), 116-123, 2017 | 197 | 2017 |
| Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management JM Pogue, T Mann, KE Barber, KS Kaye Expert review of anti-infective therapy 11 (4), 383-393, 2013 | 183 | 2013 |
| Cefiderocol: a novel agent for the management of multidrug-resistant Gram-negative organisms JY Wu, P Srinivas, JM Pogue Infectious diseases and therapy 9, 17-40, 2020 | 180 | 2020 |
| Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa JM Pogue, KS Kaye, MP Veve, TS Patel, AT Gerlach, SL Davis, ... Clinical Infectious Diseases 71 (2), 304-310, 2020 | 176 | 2020 |
| Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship D Marchaim, T Chopra, A Bhargava, C Bogan, S Dhar, K Hayakawa, ... Infection Control & Hospital Epidemiology 33 (8), 817-830, 2012 | 172 | 2012 |
| Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens JM Pogue, KS Kaye, DA Cohen, D Marchaim Clinical Microbiology and Infection 21 (4), 302-312, 2015 | 162 | 2015 |
| Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin EJ Zasowski, KP Murray, TD Trinh, NA Finch, JM Pogue, RP Mynatt, ... Antimicrobial agents and chemotherapy 62 (1), 10.1128/aac. 01684-17, 2018 | 157 | 2018 |
| Ceftazidime/avibactam, meropenem/vaborbactam, or both? Clinical and formulary considerations JM Pogue, RA Bonomo, KS Kaye Clinical Infectious Diseases 68 (3), 519-524, 2019 | 155 | 2019 |
| Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae JT Thaden, JM Pogue, KS Kaye Virulence 8 (4), 403-416, 2017 | 141 | 2017 |
| Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli T Chopra, D Marchaim, J Veltman, P Johnson, JJ Zhao, R Tansek, ... Antimicrobial agents and chemotherapy 56 (7), 3936-3942, 2012 | 137 | 2012 |
